RS20050775A - A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor - Google Patents

A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor

Info

Publication number
RS20050775A
RS20050775A YUP-2005/0775A YUP20050775A RS20050775A RS 20050775 A RS20050775 A RS 20050775A YU P20050775 A YUP20050775 A YU P20050775A RS 20050775 A RS20050775 A RS 20050775A
Authority
RS
Serbia
Prior art keywords
pharmaceutical composition
digitalis
effect
phosphodiesterase inhibitor
active agent
Prior art date
Application number
YUP-2005/0775A
Other languages
Serbian (sr)
Inventor
Janos Egri
Original Assignee
Synosens Kutato Es Fejleszto Kft,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosens Kutato Es Fejleszto Kft, filed Critical Synosens Kutato Es Fejleszto Kft,
Publication of RS20050775A publication Critical patent/RS20050775A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Automotive Seat Belt Assembly (AREA)

Abstract

The invention refers to a cardiotonic pharmaceutical composition having enhanced therapeutical width. The pharmaceutical composition of the invention comprises (a) an active ingredient having the effect of digitalis and (b) a cGMP phosphodiesterase inhibitor and one or more conventional carrier(s).
YUP-2005/0775A 2003-04-15 2004-04-14 A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor RS20050775A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0300985A HUP0300985A2 (en) 2003-04-15 2003-04-15 Pharmaceutical composition having improved spectrum
PCT/HU2004/000036 WO2004091632A1 (en) 2003-04-15 2004-04-14 A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor

Publications (1)

Publication Number Publication Date
RS20050775A true RS20050775A (en) 2007-12-31

Family

ID=90001684

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0775A RS20050775A (en) 2003-04-15 2004-04-14 A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor

Country Status (7)

Country Link
EP (1) EP1648470A1 (en)
JP (1) JP2006523667A (en)
CA (1) CA2522143A1 (en)
ES (1) ES2363087T3 (en)
HU (1) HUP0300985A2 (en)
RS (1) RS20050775A (en)
WO (1) WO2004091632A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128035A2 (en) * 2005-05-26 2006-11-30 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
MX369832B (en) 2012-05-18 2019-11-22 Luoda Pharma Ltd Liquid formulation.

Also Published As

Publication number Publication date
HUP0300985A2 (en) 2005-07-28
JP2006523667A (en) 2006-10-19
ES2363087T3 (en) 2011-07-20
EP1648470A1 (en) 2006-04-26
WO2004091632A1 (en) 2004-10-28
CA2522143A1 (en) 2004-10-28
HUP0300985D0 (en) 2003-06-28

Similar Documents

Publication Publication Date Title
MXPA04003668A (en) Type 4 phosphodiesterase inhibitors and uses thereof.
NO20071078L (en) Antiviral compounds
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
IS7817A (en) Phenylalanine derivatives which dipeptidyl peptidase inhibit the treatment or prevention of diabetes.
AU3652102A (en) Compounds and their uses
PT1727551E (en) Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the rsv fusion protein
PT1727550E (en) Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein
TNSN05265A1 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
HK1093064A1 (en) Thienopyrimidine derivatives as potassium channel inhibitors
HN2001000244A (en) SPIROPIRIMIDIN INHIBITORS - 2, 4, 6 - TRIONA METALOPROTEINASAS.
MXPA05012812A (en) Compounds, methods and pharmaceutical compositions for inhibiting parp.
TW200612950A (en) Quinazolinedione derivatives as PARP inhibitors
CR7182A (en) BENZOILSUFANAMIDS AND SULFONYLBENZAMIDINS THAT ARE USED AS ANTITUMURAL AGENTS
MY139355A (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
TW200518771A (en) Formulations for coated microprojections containing non-volatile counterions
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
MX2009005011A (en) Imidazopyrazines as protein kinase inhibitors.
TR199901191T2 (en) Use of benzamidoaldehydes as cysteine protease inhibitors.
GB0226434D0 (en) Combination product
TW200602062A (en) Improved formulations of 6-mercaptopurine
TW200621773A (en) Bicyclononene derivatives
MXPA05006368A (en) Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2.
BRPI0411864A (en) combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
WO2004028474A3 (en) Caspase inhibitors as anticancer agents
UA87312C2 (en) COMPOSITION FOR AEROSOL INHALATION OF β-AGONISTS